Advanced Care Scripts (ACS), a part of
) Specialty Care Group, has been recently included in the limited
distribution network for
) and Astellas Pharma's Xtandi (enzalutamide).
On August 31, 2012, the U.S. Food and Drug Administration (FDA) had
approved Xtandi for the treatment of metastatic
castration-resistant prostate cancer in patients who have earlier
The addition to the limited distribution agreement for Xtandi will
enable ACS to provide access and reimbursement support to patients
and physicians. ACS will also provide access to the drug to
entitled patients who do not have insurance.
Omnicare's Specialty Care Group has witnessed solid growth with
market share gains for specialty drugs. Revenues from the Specialty
Care Group surged 25.7% year over year to $330.1 million in the
most recent quarter. The Specialty Care Group continues to be the
company's revenue driver. Extending into specialty-focused
platforms and additional disease states such as oncology will allow
Omnicare to accelerate growth for its Specialty Care Group in the
Omnicare is a market leading provider of long-term care pharmacy
services and health care environment for individuals directly and
indirectly, through subsidiaries, across North America. It competes
National Healthcare Corp.
) in certain niche segments.
Omnicare currently retains a Zacks #3 Rank, which translates into a
short-term Hold rating. The company's performance in the most
recent quarter negated external pricing pressure and reimbursement
cuts. Omnicare has shown significant improvement in margins,
attributable to new generics introductions and cost containment
Moreover, generic launches in the next few quarters present a major
opportunity due to Omnicare's direct access to manufacturers and
current greater exposure to the institutional pharmacy channel than
in the past couple of years. However, the company continues to rely
on Medicare and Medicaid programs for a major share of its
MEDIVATION INC (MDVN): Free Stock Analysis
NATL HEALTHCARE (NHC): Free Stock Analysis
OMNICARE INC (OCR): Free Stock Analysis Report
PHARMERICA CORP (PMC): Free Stock Analysis
To read this article on Zacks.com click here.